Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Updates in Surgery|June 30, 2019
Selecting treatment sequence for patients with incidental gallbladder cancer: a neoadjuvant approach versus upfront surgeryLeonid Cherkassky, William Jarnagin
Surgical Oncology Clinics of North America|September 2, 2019
Gallbladder Cancer: Managing the Incidental DiagnosisLeonid Cherkassky, Michael D'Angelica
Journal of Surgical Oncology|December 31, 2013
The role of preoperative positron emission tomography/computed tomography (PET/CT) in patients with high-risk melanomaMaya Barsky, Leonid Cherkassky, Michael Vezeridis, et al.
Cancer Cell|November 13, 2019
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid TumorsRachel Grosser, Leonid Cherkassky, Navin Chintala, et al.
Journal of Surgical Case Reports|November 3, 2021
A case from the future of HPB surgical oncology: resection of biliary tract cancer after immunotherapyVikas Satyananda, Konstantinos Chouliaras, Leonid Cherkassky, et al.
Cancer Cell|April 29, 2022
Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumorsLeonid Cherkassky, Zhaohua Hou, Alfredo Amador-Molina, et al.
Annals of Surgical Oncology|January 17, 2023
High Risk, High Reward: Frailty in Colorectal Cancer Surgery is Associated with Worse Postoperative Outcomes but Equivalent Long-Term Oncologic OutcomesEihab Abdelfatah, Vicente Ramos-Santillan, Leonid Cherkassky, et al.
American Journal of Cancer Research|August 15, 2022
An immune-inflamed tumor microenvironment as defined by CD8 score is associated with favorable oncologic outcomes in hepatocellular carcinoma independent of measures of tumor mutational burdenLeonid Cherkassky, Masanori Oshi, Eihab Abdelfatah, et al.
Cancers|January 22, 2021
Enhanced DNA Repair Pathway is Associated with Cell Proliferation and Worse Survival in Hepatocellular Carcinoma (HCC)Masanori Oshi, Tae Hee Kim, Yoshihisa Tokumaru, et al.
Journal of Surgical Oncology|August 19, 2024
Chemotherapy switch for nonresponse or progression on neoadjuvant chemotherapy for pancreatic adenocarcinomaBrendan L Hagerty, Fatemeh Fekrmandi, Tyce Schneider, et al.
Pageof 2